|
Feb 18
|
|
$228.72
$228.72
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Incyte Remains Undervalued As Opzelura And Ni...
|
|
Feb 18
|
|
$228.72
$228.72
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Harbor Dividend Growth Leaders ETF Q4 Contrib...
|
|
Feb 18
|
|
$228.72
$228.72
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
What's going on in today's session: S&P500 mo...
|
|
Feb 18
|
|
$228.72
$228.72
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
IXJ: Healthcare Sector Dashboard For February
|
|
Feb 18
|
|
$228.72
$228.72
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Piper Sandler Maintains Overweight on AbbVie,...
|
|
Feb 17
|
|
$232.86
$228.72
-1.8%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Assessing AbbVie (ABBV) Valuation After Stron...
|
|
Feb 17
|
|
$232.86
$228.72
-1.8%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Facial Injectable Analysis Report 2025: An $1...
|
|
Feb 17
|
|
$232.86
$228.72
-1.8%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
10 Health Care Stocks With Whale Alerts In To...
|
|
Feb 17
|
|
$232.86
$228.72
-1.8%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie: Dominating Immunology While Building ...
|
|
Feb 16
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie Conference: Year-End HS Readouts, SubQ...
|
|
Feb 15
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
1 No-Brainer Dividend Stock to Buy on the Dip
|
|
Feb 15
|
|
$231.50
$228.72
-1.2%
|
LONG
|
Finnhub News
|
The headline recommends specific dividend stocks for a long-term investment strategy, indicating confidence in their future performance. |
Finnhub - ABBV
3 Dividend Stocks to Hold for the Next 20 Yea...
|
|
Feb 14
|
|
$231.50
$228.72
-1.2%
|
SHORT
|
Finnhub News
|
A lawsuit involving AbbVie's Botox and Medicare pricing highlights potential financial and regulatory risks for the company. |
Finnhub - ABBV
AbbVie’s Botox Lawsuit Puts Medicare Pricing ...
|
|
Feb 14
|
|
$231.50
$228.72
-1.2%
|
LONG
|
Finnhub News
|
The headline recommends buying resilient dividend stocks as an opportunity during a market sell-off. |
Finnhub - ABBV
2 Unstoppable Dividend Stocks to Buy If There...
|
|
Feb 14
|
|
$231.50
$228.72
-1.2%
|
SHORT
|
Finnhub News
|
Kraft Heinz received a rating downgrade, indicating a negative outlook for the company. |
Finnhub - ABBV
Kraft Heinz: Looks Like Berkshire Got Its Wis...
|
|
Feb 13
|
|
$231.50
$228.72
-1.2%
|
SHORT
|
Finnhub News
|
A prominent investor has significantly reduced their holdings in Abbott Laboratories, suggesting a less favorable view of the stock. |
Finnhub - ABBV
Abbott Laboratories: A Key Reduction in Rober...
|
|
Feb 13
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Where is AbbVie Inc. (ABBV) Headed According ...
|
|
Feb 13
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Merck stock upside: Why Deutsche Bank sees 26...
|
|
Feb 13
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie Inc. (ABBV) Presents at Piper Sandler ...
|
|
Feb 13
|
|
$231.50
$228.72
-1.2%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
West Pharmaceutical Services (WST) Is Up 5.2%...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
This Is Graco’s Dividend Score After Paying I...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie Inc. stock outperforms competitors on ...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
IRWD Rises 307% in 6 Months: Is This an Indic...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Is It Too Late To Consider AbbVie (ABBV) Afte...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
1 Reason I'm Never Selling AbbVie Stock
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie Inc. (ABBV) Achieves Record Net Sales ...
|
|
Feb 12
|
|
$227.50
$228.72
+0.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says...
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie sues US health agency over Botox price...
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOT...
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
AVOID
|
Eric Burlison
Representative (R-MO)
|
Rep. Burlison discusses the "Khloe Cole Act," which the DOJ helped draft, creating a "private right of action" (ability to sue) for patients to sue doctors and pharma companies for gender-affirming care (puberty blockers/surgeries) with a lengthy statute of limitations. Bondi expresses strong support ("proud to work hand in hand"). This legislation opens a new floodgate of medical malpractice and product liability litigation against hospitals and pharmaceutical companies involved in these treatments. Similar to the opioid crisis, creating a specific legal framework for mass torts against healthcare providers creates unquantifiable liability overhangs for specific hospital chains and drug manufacturers. The legislation may not pass Congress; the number of claimants may be statistically insignificant to large cap pharma earnings. |
CNBC
Attorney General Pam Bondi testifies before H...
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
AbbVie Sues HHS Over Selection Of Botox For I...
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
2 Urgent Sells And 2 No Brainer Dividend Buys
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
P/E Ratio Insights for AbbVie
|
|
Feb 11
|
|
$220.89
$228.72
+3.5%
|
N/A
|
Finnhub News
|
— |
Finnhub - ABBV
The 5 Most Interesting Analyst Questions From...
|